BioPharmaTrend
News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech
  • Interviews
  • Business Intelligence
  • Case Studies
Intelligence
  • Business Intelligence
  • Case Studies
  • Lab
  • Membership
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • NeuroTech
This company is included in Intelligence Lab

CureVac

CureVac logo

Website
http://www.curevac.com
Founded
2000

Founded in 2000, the biopharmaceutical company CureVac is technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA). Here, the company follows the body’s own principle in which mRNA is used as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The RNA people pursue the ambitious goal of making the first mRNA-based drug available to people in need.


Articles Mentioning This Company

Beyond Traditional Medicine: Exploring the Revolutionary Therapies Transforming Patient Care

March 17, 2023     Articles
Biotechnology has revolutionized the healthcare industry, and with the increasing demand for advanced therapies, the focus has shifted towards innovative therapeutic modalities. In this blog article, we will explore some of the cutting-edge therapeutic modalities that have the potential to transform patient care.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • Business Intelligence
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Lab Access
  • Lab Membership
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.